Newswise — La Jolla, Calif. – Oct. 25, 2017 - Scientists at the Scripps Translational Science Institute and The Scripps Research Institute have announced the launch of a smartphone-app research study that seeks to understand how receiving personal genetic risk information impacts heart health decisions.
The MyGeneRank app allows individuals with genetic data from 23andMe to obtain an estimated genetic risk score for coronary artery disease. Surveys and Apple HealthKit data will be used to determine if this information helped guide decision-making related to lifestyle modification and use of statin medications.
Many health conditions, including coronary artery disease (CAD), are caused by a combination of our environment, behaviors and genes. While patients can control some factors that may impact their chances of developing disease, the contribution of their genes remains encoded in their DNA throughout their lives.
Now, extensive research has shown that a genetic risk score can be used to identify people with low, intermediate and high risk for CAD. It has also been determined that the use of cholesterol-lowering drugs, known as statins, provides greater benefit and protection against disease for people with a high genetic risk for CAD. Additionally, despite their inherited genetic risks, individuals have the ability to offset much of their genetic risk for CAD by maintaining healthy lifestyle habits.
Ali Torkamani, Director of Genomics at the Scripps Translational Science Institute, and Associate Professor of Integrative Structural and Computational Biology at The Scripps Research Institute, leads the team behind MyGeneRank. “We want to determine whether or not knowledge of genetic risk impacts decision-making when it comes to health behaviors or statin therapy,” says Torkamani. “Using ResearchKit, we can reach more participants via iPhone, expanding this study far beyond geographic barriers.”
The MyGeneRank mobile app is built using Apple’s ResearchKit, an open source framework that enables researchers and programmers to build customized mobile apps for research purposes. With user permission, the app connects with the 23andMe application program interface and automatically calculates and returns a genetic risk score for coronary artery disease.
In addition, the app calculates a 10-year absolute risk estimate for an adverse coronary event, such as heart attack, using a combination of genetic and clinical factors. Users are able to adjust behavioral risk factors to see the influence of lifestyle habits on their overall risk.
Study participants are asked to complete a survey immediately upon receipt of their score, as well as six months later to determine whether knowledge of their genetic risk influenced their health decisions. Through its integration with the Health app on iPhone, individuals can choose to share their health, activity and nutrition data with researchers to further assess changes in behavior.
“We are excited to launch a unique study that combines an iOS app and genomics to help guide important health decisions,” says Eric Topol, MD, Founder and Director of the Scripps Translational Science Institute and Professor of Molecular Medicine at The Scripps Research Institute. “Not only does participating in the study arm individuals with their own data, but it also gives them the opportunity to participate in new type of research – one that is driven by and for patients.”
When discussing next steps, Torkamani says, “the goal is to expand the app’s offering of genetic risk scores to other diseases, as well as support the Android operating system, and integrate additional commercial personal genetic data platforms.”
Download MyGeneRank from the App Store.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.
About the Scripps Translational Science Institute
The Scripps Translational Science Institute (STSI) of The Scripps Research Institute focuses on individualized medicine, using the tools of digital medicine and genomics to better understand each person and render more effective healthcare. In 2016, STSI was awarded a grant for over $200M by the National Institutes of Health’s Precision Medicine Initiative to lead the All of Us Research Program’s Participant Center. STSI is further supported, since 2008, by the flagship NIH Clinical and Translational Science Award to promote human health and train future leaders in biomedicine. For more information, visit www.stsiweb.org.